glimepiride (Amarel)

Subscribe to Selected New Research on glimepiride

148 relevant articles (18 outcomes, 49 trials/studies) found for this Drug

Description: structure given in first source

Also Known As:

Amarel; Amaryl; 1-(4-(2-(3-ethyl-4-methyl-2-oxo-3-pyrrolinecarboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea; Aventis Behring brand of glimepiride; Aventis Pharma brand of glimepiride; Aventis brand of glimepiride; HOE 490; HOE-490; Hoechst brand of glimepiride; Lacer brand of glimepiride; Roname

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Urea: 6681

Sulfonylurea Compounds: 28

glimepiride: 148

Sulfur Compounds: 82

Sulfones: 120

Sulfonylurea Compounds: 28

glimepiride: 148

Experts

1.	Ciccarelli, Leonardina: 7 articles (05/2006 - 02/2003)
2.	Derosa, Giuseppe: 7 articles (05/2006 - 02/2003)
3.	Cicero, Arrigo F G: 5 articles (05/2006 - 05/2004)
4.	Piccinni, Mario N: 5 articles (05/2006 - 05/2004)
5.	Gaddi, Antonio: 4 articles (05/2006 - 05/2004)
6.	Ferrari, Ilaria: 4 articles (05/2006 - 05/2005)
7.	Fogari, Roberto: 4 articles (11/2005 - 02/2003)
8.	Salvadeo, Sibilla: 4 articles (11/2005 - 05/2005)
9.	Pricolo, Fabio: 3 articles (05/2006 - 09/2005)
10.	Ragonesi, Pietro D: 3 articles (05/2006 - 05/2004)

Related Diseases

1.	Insulin Resistance 02/01/2005 - "Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone." 02/01/2006 - "CONCLUSIONS: Glimepiride appears to improve insulin resistance and atherosclerotic disorders." 06/01/2005 - "In conclusion, switching conventional SUs to glimepiride reduced insulin resistance without improving glycemic control" 02/01/2003 - "CONCLUSIONS: Glimepiride remarkably improved insulin resistance, suggested by a significant reduction in HOMA-IR, an increase in MCR-g, and a reduction in HbA(1c) without changing extrapancreatic beta-cell function and urine CPR" 11/01/2005 - "We can conclude that the association of a thiazolinedione to the glimepiride treatment of type 2 diabetic subjects with metabolic syndrome is associated to a significant improvement in the long-term blood pressure control, related to a reduction in insulin-resistance." Get all the results and reference details, order at left...
2.	Syndrome 03/01/2006 - "We evaluated 99 type 2 diabetic patients with metabolic syndrome (48 males and 47 females; 23 males and 24 females, aged 52 +/- 5 with glimepiride; 25 males and 23 females, aged 54 +/- 4 with cglitazone)" 11/01/2005 - "We can conclude that the association of a thiazolinedione to the glimepiride treatment of type 2 diabetic subjects with metabolic syndrome is associated to a significant improvement in the long-term blood pressure control, related to a reduction in insulin-resistance." 07/01/2005 - "CONCLUSIONS: We conclude that the addition of a thiazolinedione to glimepiride treatment in type 2 diabetic subjects with the metabolic syndrome is associated with a slight but significant reduction of PAI-1 value, related to a similar reduction in insulinresistance." 11/01/2005 - "Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride." 11/01/2005 - "The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride" Get all the results and reference details, order at left...
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2003 - "OBJECTIVE: The goal of this study was to evaluate the efficacy and safety of glimepiride, a long-acting sulfonylurea, as an adjunct to diet/exercise in Mexican Americans with type 2 diabetes mellitus" 01/01/2003 - "Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study." 11/01/2001 - "CONCLUSION: This large-scale study, conducted under conditions approximating to current medical practice, confirms that glimepiride has a favourable risk-benefit ratio in type 2 diabetes mellitus" 07/01/1997 - "The aim of the present study was to assess the beta cell response to glimepiride, administered orally, during and following a hyperglycaemic clamp in 14 NIDDM patients (7 males), aged 62.5 (St. Dev" 09/01/1996 - "The objective of this paper is to obtain an overview of the safety and tolerance of glimepiride by presenting results from the clinical trials in patients with non-insulin-dependent diabetes mellitus that were conducted during the development of this new product" Get all the results and reference details, order at left...
4.	Hypoglycemia (Reactive Hypoglycemia) 10/01/2005 - "The overall incidence of hypoglycemia, however, was 51.2% in the glimepiride group and 8.3% in the placebo group (P < 0.001)" 07/01/2000 - "Persistent hyperinsulinemic hypoglycemia in newborn associated with glimepiride treatment at the beginning of pregnancy]" 03/01/2003 - "In clinical studies, glimepiride was generally associated with a lower risk of hypoglycemia and less weight gain than other SUs" 07/01/2001 - "Outside of Japan, several clinical studies have demonstrated that glimepiride shows less hypoglycemia and no weight gain" 05/01/2003 - "However, we also found an 8 x 4 mm hypoechoic tumor in the cauda pancreatis of a patient with severe factitial hypoglycemia (glimepiride)" Get all the results and reference details, order at left...
5.	Body Weight (Weight, Body) 07/01/2003 - "Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study." 12/01/2003 - "CONCLUSIONS/INTERPRETATION: Initial treatment of Type 2 diabetes with glimepiride was associated with a significantly greater decrease in body weight and body mass index than treatment with glibenclamide, while providing equivalent glycaemic control." 05/01/2006 - "This open study showed a progressive decrease of fasting blood glucose and glycated haemoglobin (HbA1c) levels with glimepiride (titrated from 1 to 6 mg/day, as needed, with a mean daily dose of 2,6 mg), together with a simultaneous slight reduction in body weight and without any increase of the hypoglycaemic risk" 12/01/2003 - "AIMS/HYPOTHESIS: Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice" 09/01/2007 - "The addition of sitagliptin was generally well tolerated, with a modest increase in hypoglycaemia and body weight, consistent with glimepiride therapy and the observed degree of glycaemic improvement." Get all the results and reference details, order at left...
49 Diseases and 148 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Metformin (Glucophage)
3.	Glyburide (Glibenclamide)
4.	rosiglitazone (Avandia)
5.	glargine (insulin glargine)
6.	pioglitazone (Actos)
7.	Glucose (Dextrose)
8.	Blood Glucose (Blood Sugar)
9.	PPAR gamma
10.	Glipizide (Glucotrol)
65 Drugs and Important Bio-Agents and 114 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Cardiopulmonary Resuscitation (CPR)
2.	Angioplasty (Angioplasties)
3.	Diet Therapy (Therapy, Diet)
3 Therapies and Procedures and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>